Ignite Creation Date:
2025-12-26 @ 12:15 PM
Ignite Modification Date:
2026-04-19 @ 5:14 PM
Study NCT ID:
NCT07031700
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-06-22
First Post:
2025-03-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
FL-RR-MOS01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None